Epimmune Inc. has entered into an evaluation and license option agreement with Immuno-Designed Molecules, S.A. (IDM) for certain cancer antigens for use in IDM’s ex vivo cancer therapy program. Under the terms of the agreement, IDM will have 120 days from the date of the option agreement to evaluate the epitopes and exercise its option to license certain patented and non-patented rights to Epimmune’s universal cancer epitope packages for use in ex vivo cancer therapy.
Should IDM exercise its rights under the agreement, it will have a non-exclusive license to use the epitopes in connection with its Dendritophage ex vivo technology.
Epimmune received an evaluation license fee and is further entitled to receive a license fee if IDM exercises its option to obtain license rights, and pre-commercialization milestones and royalties on product sales if IDM develops products utilizing the Epimmune technology.
Epimmune‘s cancer epitopes (antigen fragments) are derived from multiple tumor associated antigens and contain both native and analog epitope sequences.
IDM’s technology consists of monocyte derived dendritic cells (Dendritophages) loaded in vitro with tumor antigens or epitopes and then reinjected to the patient.
Epimmune Inc. is focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body’s immune system.